Correction to: Project honeybee: Clinical applications for wearable biosensors.

The original version of this article unfortunately contained a mistake.

Project honeybee: Clinical applications for wearable biosensors.

Please provide an abstract of 150 to 250 words. The abstract should not contain any undefined abbreviations or unspecified references. The Project Honeybee Observational Clinical Trials were 12-month studies designed to validate the use of commercially available ambulatory medical devices costing $50-$300 for clinical applications. Each trial had a patient population of about 15-30 subjects with a broad range of disease types including heart failure, diabetes, sepsis, and Parkinson's disease. Over 30 supported proposals were funded in the 4-year period, as well as the creation of a database of all commercially available devices. Each year a call for proposals was published within ASU and Mayo Clinic Arizona. Proposals were selected for funding by a committee of ASU faculty from engineering, nursing, and exercise physiology departments. The progress of each research trial was monitored through monthly colloquia with the nursing, biomedical engineering, computer science, and nutrition graduate research assistants, to discuss the challenges and opportunities arising with each research trial. PIs were required to report on study progress 6 months into the trial period and 3 months following the conclusion of the 12-month project. The project was very successful in meeting our goals of testing consumer wearable devices on patients for a variety of conditions across a variety of clinical settings in the greater Phoenix community. The following clinical sites participated in one or more of these clinical trials: Adelante Healthcare, Arizona Arrhythmia Consultants, Arizona Cardiology Group, Banner University Medical Center, Barrow Neurological Institute, Honor Health, Mayo Clinic, and St Joseph's Hospital. A total of 12 ASU faculty and 39 clinicians participated.

Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan.

Most cases of oral squamous cell carcinoma (OSCC) develop from visible oral potentially malignant disorders (OPMDs). The latter exhibit heterogeneous subtypes with different transformation potentials, complicating the early detection of OSCC during routine visual oral cancer screenings. To develop clinically applicable biomarkers, we collected saliva samples from 96 healthy controls, 103 low-risk OPMDs, 130 high-risk OPMDs, and 131 OSCC subjects. These individuals were enrolled in Taiwan's Oral Cancer Screening Program. We identified 302 protein biomarkers reported in the literature and/or through in-house studies and prioritized 49 proteins for quantification in the saliva samples using multiple reaction monitoring-MS. Twenty-eight proteins were successfully quantified with high confidence. The quantification data from non-OSCC subjects (healthy controls + low-risk OPMDs) and OSCC subjects in the training set were subjected to classification and regression tree analyses, through which we generated a four-protein panel consisting of MMP1, KNG1, ANXA2, and HSPA5. A risk-score scheme was established, and the panel showed high sensitivity (87.5%) and specificity (80.5%) in the test set to distinguish OSCC samples from non-OSCC samples. The risk score >0.4 detected 84% (42/50) of the stage I OSCCs and a significant portion (42%) of the high-risk OPMDs. Moreover, among 88 high-risk OPMD patients with available follow-up results, 18 developed OSCC within 5 y; of them, 77.8% (14/18) had risk scores >0.4. Our four-protein panel may therefore offer a clinically effective tool for detecting OSCC and monitoring high-risk OPMDs through a readily available biofluid.

The case for early detection.

Early detection represents one of the most promising approaches to reducing the growing cancer burden. It already has a key role in the management of cervical and breast cancer, and is likely to become more important in the control of colorectal, prostate and lung cancer. Early-detection research has recently been revitalized by the advent of novel molecular technologies that can identify cellular changes at the level of the genome or proteome, but how can we harness these new technologies to develop effective and practical screening tests?

Nobel Lecture. Yeast and cancer.

The discovery of genes that control cell division in yeast, and their relation to cancer, is reviewed.

Yeast and cancer.

The discovery of genes that control cell division in yeast, and their relation to cancer, is reviewed.

Perspective: a program to improve protein biomarker discovery for cancer.

Biomarkers for cancer risk, early detection, prognosis, and therapeutic response promise to revolutionize cancer management. Protein biomarkers offer tremendous potential in this regard due to their great diversity and intimate involvement in physiology. An effective program to discover protein biomarkers using existing technology will require team science, an integrated informatics platform, identification and quantitation of candidate biomarkers in disease tissue, mouse models of disease, standardized reagents for analyzing candidate biomarkers in bodily fluids, and implementation of automation. Technology improvements for better fractionation of the proteome, selection of specific biomarkers from complex mixtures, and multiplexed assay of biomarkers would greatly enhance progress.